Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer. The protocol of this therapy was as follows: On day 1, 500 mg/body cyclophosphamide (CPM) was administered by drip infusion, and on day 2, 200 mg/m2 methotrexate (MTX) was infused intravenously for 30 min; immediately after, 500 mg/body 5-fluorouracil (5-FU) was injected by bolus infusion for 5-10 min. On day 3, 24 hours after MTX administration, leucovorin rescue was added. This combination chemotherapy was repeated every two weeks. As a result, 35 of 52 patients were evaluable and the response rate (CR + PR) was investigated; 2/21 (9.5%) for gastric, 2/7 (28.6%) for breast, and 0% for miscellaneous. As complications for side effect, general fatigue, anorexia, nausea, vomiting and stomatitis were observed symptomatically, and leukopenia and thrombocytopenia were recognized in laboratory data as dose limiting factors.
 ...
PMID:[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. 271 79

We report 2 patients with recurrent gastric cancer treated by combined chemotherapy of TS-1 and low-dose cis-platinum (TS-1/LCDDP). Who both obtained long-term survival while maintaining good QOL. Case 1: A 60-year-old man underwent total gastrectomy for gastric cancer (pT3, pN2, Stage III B). Three months after surgery, multiple liver metastases were identified, for which TS-1/LCDDP therapy (TS-1 100 mg/body/day, CDDP 10 mg/body/week; 1 course for 4 weeks) was started without hospitalization. After CR was obtained after 4 courses, an additional 4 courses were carried out. At present, 1 year and 11 months have passed since the initial treatment, and CR has been maintained. Regarding adverse events, only grade-1 pigmentation was observed. Case 2: A 65-year-old man with gastric cancer (pT3, pN1, Stage III A) underwent distal gastrectomy. One year after surgery, CT showed both multiple liver and pulmonary metastases. Twelve courses of TS-1/LCDDP therapy have been carried out for 2 years and 4 months. Therapeutic effect was NC, but the patient was able to tolerate the treatments as an outpatient without any subjective symptoms. Leukopenia (grade 2), pigmentation, stomatitis and nausea (grade 1) were observed. Both patients received TS-1/LCDDP therapy as outpatients with good QOL and performance status (0). Recently, chemotherapy for recurrent cancer has been focusing on long-term survival and maintenance of QOL, instead of tumor shrinkage. These results suggest that TS-1/LCDDP treatment is useful as a first-line chemotherapy for patients with recurrent gastric cancer.
 ...
PMID:[Two cases of recurrent gastric cancer treated by combined chemotherapy of TS-1 and low-dose cis-platinum]. 1517 Sep 89